Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain containing GRB2 like, endophilin B1 (SH3GLB1)
- Target
- SH3GLB1
- Molecular classification
- BAR family protein (Bin/Amphiphysin/Rvs), Membrane remodeling protein, Adaptor protein (SH3 domain), Other
01
Overview
SH3 domain containing GRB2 like, endophilin B1 (SH3GLB1, also known as Endophilin-B1 or Bif-1) is a membrane remodeling protein crucial for mitochondrial fission/fusion, autophagy, and apoptosis. It contains both an N-BAR domain (for membrane curvature and dimerization) and a C-terminal SH3 domain (enabling interactions with proteins bearing proline-rich regions). SH3GLB1 promotes the formation of autophagosomes through modulation of PI3KC3 and interacts with apoptosis regulators such as Bax. Dysregulation of SH3GLB1 is linked to cancer (as a putative tumor suppressor) and impacts cell death pathways in both neuronal and non-neuronal cells[1][3][5].
- Other names
- Endophilin-B1Bif-1Bax-interacting factor 1KIAA0491CGI-61PPP1R70SH3 domain-containing GRB2-like protein B1dJ612B15.2protein phosphatase 1, regulatory subunit 70testicular tissue protein Li 172SH3GLB2 (paralog)
02
Mechanism of action
Not directly established. By analogy: - Modulation of Bax/Bcl-2 interactions - Regulation of PI3KC3 (class III phosphatidylinositol 3-kinase) activity - Influence on autophagy induction - Drugs targeting upstream or downstream effectors in these pathways may indirectly affect SH3GLB1 activity.
03
Biological functions
Mitochondrial fission and fusionApoptosis (pro-apoptotic and anti-apoptotic roles depending on isoform/cell type)Autophagy (regulation and induction)Maintenance of mitochondrial morphologyEndocytic trafficking and cytokinesisProtein-protein interactions (especially with proline-rich motifs)
04
Disease associations
Cancer (tumor suppressor role; loss of function in various cancers)Neurodegenerative disease (neuron survival, mitochondrial dynamics)Noonan Syndrome 5 (genetic association)Other (broad involvement in cell death regulation)
05
Safety considerations
Therapeutic targeting may affect mitochondrial function and cell viabilityModulation could impact neuronal survival or increase apoptosis risk, possibly leading to unintended cell death in non-targeted cells
06
Interacting drugs
None directly listed in current sources. However, the biological pathways (apoptosis, autophagy) suggest possible relevance to investigational compounds targeting Bcl-2 family proteins, PI3K/PI3KC3, or autophagy modulators. No FDA-approved drugs directly target SH3GLB1.
07
Biomarkers
Loss of SH3GLB1 expression linked to certain cancers [potential cancer biomarker]Autophagic activity (e.g., LC3 localization) in experimental conditions
Beyond the preview
Go deeper on SH3 domain containing GRB2 like, endophilin B1 (SH3GLB1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH3 domain containing GRB2 like, endophilin B1 (SH3GLB1).